These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21336546)

  • 1. Immunotherapy for EBV-associated malignancies.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
    Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Amadori A; Rosato A
    Expert Opin Biol Ther; 2008 Sep; 8(9):1265-94. PubMed ID: 18694349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
    Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
    J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
    Huls MH; Rooney CM; Heslop HE
    Acta Haematol; 2003; 110(2-3):149-53. PubMed ID: 14583675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
    Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
    Gottschalk S; Heslop HE; Roon CM
    Adv Cancer Res; 2002; 84():175-201. PubMed ID: 11883527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy for EBV-associated malignancies.
    Gottschalk S; Heslop HE; Rooney CM
    Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
    Chia WK; Teo M; Wang WW; Lee B; Ang SF; Tai WM; Chee CL; Ng J; Kan R; Lim WT; Tan SH; Ong WS; Cheung YB; Tan EH; Connolly JE; Gottschalk S; Toh HC
    Mol Ther; 2014 Jan; 22(1):132-9. PubMed ID: 24297049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
    Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
    Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.